vs

Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.

CB Financial Services, Inc. is the larger business by last-quarter revenue ($13.8M vs $8.4M, roughly 1.7× Immunovant, Inc.). On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 19.9%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-59.8M).

CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

CBFV vs IMVT — Head-to-Head

Bigger by revenue
CBFV
CBFV
1.7× larger
CBFV
$13.8M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+120.9% gap
IMVT
140.7%
19.9%
CBFV
More free cash flow
CBFV
CBFV
$77.0M more FCF
CBFV
$17.2M
$-59.8M
IMVT

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
CBFV
CBFV
IMVT
IMVT
Revenue
$13.8M
$8.4M
Net Profit
$-75.3M
Gross Margin
Operating Margin
38.1%
-896.2%
Net Margin
-899.0%
Revenue YoY
19.9%
140.7%
Net Profit YoY
-26.7%
EPS (diluted)
$0.90
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBFV
CBFV
IMVT
IMVT
Q4 25
$13.8M
Q3 25
$2.4M
Q2 25
$13.5M
Q1 25
$12.1M
Q4 24
$13.2M
Q3 24
$12.7M
Q2 24
$12.2M
Q1 24
$13.5M
$8.4M
Net Profit
CBFV
CBFV
IMVT
IMVT
Q4 25
Q3 25
$-5.7M
Q2 25
$3.9M
Q1 25
$1.9M
Q4 24
Q3 24
$3.2M
Q2 24
$2.6M
Q1 24
$4.2M
$-75.3M
Operating Margin
CBFV
CBFV
IMVT
IMVT
Q4 25
38.1%
Q3 25
-289.8%
Q2 25
35.0%
Q1 25
19.3%
Q4 24
23.1%
Q3 24
31.2%
Q2 24
26.4%
Q1 24
37.9%
-896.2%
Net Margin
CBFV
CBFV
IMVT
IMVT
Q4 25
Q3 25
-235.2%
Q2 25
29.3%
Q1 25
15.8%
Q4 24
Q3 24
25.3%
Q2 24
21.8%
Q1 24
31.1%
-899.0%
EPS (diluted)
CBFV
CBFV
IMVT
IMVT
Q4 25
$0.90
Q3 25
$-1.07
Q2 25
$0.74
Q1 25
$0.35
Q4 24
$0.45
Q3 24
$0.60
Q2 24
$0.51
Q1 24
$0.82
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBFV
CBFV
IMVT
IMVT
Cash + ST InvestmentsLiquidity on hand
$31.7M
$635.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$157.5M
$617.8M
Total Assets
$1.5B
$666.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBFV
CBFV
IMVT
IMVT
Q4 25
$31.7M
Q3 25
$55.9M
Q2 25
$64.5M
Q1 25
$61.3M
Q4 24
$49.6M
Q3 24
$147.3M
Q2 24
$142.6M
Q1 24
$73.7M
$635.4M
Stockholders' Equity
CBFV
CBFV
IMVT
IMVT
Q4 25
$157.5M
Q3 25
$152.5M
Q2 25
$148.4M
Q1 25
$148.3M
Q4 24
$147.4M
Q3 24
$149.1M
Q2 24
$142.9M
Q1 24
$141.6M
$617.8M
Total Assets
CBFV
CBFV
IMVT
IMVT
Q4 25
$1.5B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.5B
$666.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBFV
CBFV
IMVT
IMVT
Operating Cash FlowLast quarter
$17.8M
$-59.7M
Free Cash FlowOCF − Capex
$17.2M
$-59.8M
FCF MarginFCF / Revenue
124.1%
-714.4%
Capex IntensityCapex / Revenue
4.7%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.5M
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBFV
CBFV
IMVT
IMVT
Q4 25
$17.8M
Q3 25
$4.6M
Q2 25
$4.1M
Q1 25
$4.0M
Q4 24
$6.8M
Q3 24
$3.1M
Q2 24
$-1.2M
Q1 24
$3.3M
$-59.7M
Free Cash Flow
CBFV
CBFV
IMVT
IMVT
Q4 25
$17.2M
Q3 25
$4.5M
Q2 25
$3.9M
Q1 25
$3.9M
Q4 24
$3.4M
Q3 24
$2.2M
Q2 24
$-2.4M
Q1 24
$2.3M
$-59.8M
FCF Margin
CBFV
CBFV
IMVT
IMVT
Q4 25
124.1%
Q3 25
186.5%
Q2 25
28.8%
Q1 25
32.5%
Q4 24
26.0%
Q3 24
17.4%
Q2 24
-19.6%
Q1 24
17.0%
-714.4%
Capex Intensity
CBFV
CBFV
IMVT
IMVT
Q4 25
4.7%
Q3 25
4.3%
Q2 25
1.9%
Q1 25
0.8%
Q4 24
25.1%
Q3 24
6.7%
Q2 24
10.0%
Q1 24
7.2%
1.8%
Cash Conversion
CBFV
CBFV
IMVT
IMVT
Q4 25
Q3 25
Q2 25
1.05×
Q1 25
2.11×
Q4 24
Q3 24
0.95×
Q2 24
-0.44×
Q1 24
0.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons